Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19889
Title: Acute glycemic control in diabetics. How sweet is oprimal? Pro: Sweeter is better in diabetes.
Austin Authors: Bellomo, Rinaldo 
Affiliation: Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Prahran, Melbourne, Australia
School of Medicine, University of Melbourne, Parkville, Melbourne, Australia
Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
Data Analytics Research and Evaluation (DARE) Centre, Austin Health and The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: 2018
metadata.dc.date: 2018-11-08
Publication information: Journal of intensive care 2018; 6: 71
Abstract: The optimal level of glycemic control in ICU patients has been the subject of intense investigation over the last 20 years. A pivotal study (the NICE-SUGAR study) involving more than 6,000 patients has established a target between 8 and 10 mmol/l (144 to 180 mg/dl) as the current standard of care. However, this study did not address whether patients with diabetes should be treated differently and, in particular, whether in such patients a higher glucose target should be used. The last decade has seen multiple studies aiming to describe the association between glycemia in mortality according to whether patients have or do not have diabetes and whether, if they have diabetes, pre-ICU admission glucose control (assessed by glycated hemoglobin A1c (HbA1c) levels) affects the relationship between acute glycemia and outcome. All such studies (now involving thousands and thousands of patients) have consistently shown that diabetic patients have a different relationship between acute glycemia and mortality. In particular, in diabetic patients, increasing glucose levels up to 15 mmol/l (270 mg/dl) or more are not associated with increased risk of death. In patients with a high HbA1c (> 7%) prior to ICU admission, targeting a glucose level below 10 mmol/l (180 mg/dl) is associated with increased risk compared with permissive hyperglycemia. Finally, a recent controlled study comparing a glucose target between 10 and 14 mmol/l (180 to 252 mg/dl) to a glucose target between 6 and 10 mmol/l (180 mg/dl) in diabetic patients found no advantage from tighter glycemia control. A randomized controlled study called LUCID is now underway to test the hypothesis that permissive hyperglycemia might be safer in diabetic patients admitted to the ICU. Until the results of the LUCID trial are available, the burden of evidence is in favour with targeting a more relaxed level of glycemia in diabetic patients (10-14 mmol/l; 180-252 mg/dl), especially in those with poor pre-admission glycemic control.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19889
DOI: 10.1186/s40560-018-0336-2
ORCID: 0000-0002-1650-8939
PubMed URL: 30455957
ISSN: 2052-0492
Type: Journal Article
Subjects: Diabetes
Glucose
Glycemia
Hyperglycemia
Hypoglycemia
Insulin
Randomized controlled trial
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 4, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.